Frontiers in Oncology | Breast Cancer

Review

Published on 04 Jan 2024

The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer

in Breast Cancer

Jian Zheng
Hua Hao

Frontiers in Oncology

doi 10.3389/fonc.2023.1333839

4,792 views
14 citations

Original Research

Published on 03 Jan 2024

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

in Breast Cancer

Abdul K. Siraj
Pratheesh Kumar Poyil
Divya Padmaja
Sandeep Kumar Parvathareddy
Khadija Alobaisi
Saravanan Thangavel
Roxanne Diaz
Rafia Begum
Osama Almalik
Fouad Al-Dayel

Frontiers in Oncology

doi 10.3389/fonc.2023.1286585

2,081 views
2 citations

Review

Published on 22 Dec 2023

Aromatase inhibitors: the journey from the state of the art to clinical open questions

in Breast Cancer

Daniele Generali
Rossana Berardi
Michele Caruso
Marina Cazzaniga
Ornella Garrone
Ida Minchella
Ida Paris
Carmine Pinto
Sabino De Placido

Frontiers in Oncology

doi 10.3389/fonc.2023.1249160

6,144 views
5 citations

Original Research

Published on 19 Dec 2023

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective

in Breast Cancer

Wanxian Zeng
Xueqiong Cao
Jingwen Lin
Bin Zheng
Na Li
Maobai Liu
Hongfu Cai

Frontiers in Oncology

doi 10.3389/fonc.2023.1272586

3,245 views

Review

Published on 19 Dec 2023

Incidence and influencing factors of fertility concerns in breast cancer in young women: a systematic review and meta-analysis

in Breast Cancer

Lijuan Chen
Jiali Shen
Hongzhan Jiang
Huihui Lin
Jiaxi He
Siyue Fan
Liping Yang
Doudou Yu
Rongliang Qiu
Ende Lin

Frontiers in Oncology

doi 10.3389/fonc.2023.1273529

2,677 views
3 citations

Study Protocol

Published on 19 Dec 2023

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

in Breast Cancer

Andreas R. Thomsen
Jörg Sahlmann
Peter Bronsert
Oliver Schilling
Felicia Poensgen
Annette M. May
Sylvia Timme-Bronsert
Anca-Ligia Grosu
Peter Vaupel
Jan-Olaf Gebbers

Frontiers in Oncology

doi 10.3389/fonc.2023.1275222

3,618 views
1 citation

Systematic Review

Published on 18 Dec 2023

Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis

in Breast Cancer

Xiaolin Jia
Ye Lu
Zili Xu
Qingqing Mu

Frontiers in Oncology

doi 10.3389/fonc.2023.1256747

3,990 views
4 citations

Original Research

Published on 15 Dec 2023

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

in Breast Cancer

Nour Hisham Al-Ziftawi
Shereen Elazzazy
Mohammed Fasihul Alam
Asrul Shafie
Anas Hamad
Salha Bbujassoum
Mohamed Izham Mohamed Ibrahim

Frontiers in Oncology

doi 10.3389/fonc.2023.1203684

5,542 views
6 citations

Original Research

Published on 15 Dec 2023

Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment

in Breast Cancer

Gilles Houvenaeghel
Monique Cohen
Anthony Gonçalves
Axel Berthelot
Marie Pierre Chauvet
Christelle Faure
Jean Marc Classe
Eva Jouve
Laura Sabiani
Marie Bannier

Frontiers in Oncology

doi 10.3389/fonc.2023.1287253

2,821 views
3 citations

Editorial

Published on 14 Dec 2023

Editorial: Case reports in breast cancer : 2022

in Breast Cancer

Nan Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1330225

1,686 views

Original Research

Published on 14 Dec 2023

Establishment of a lysosome-related prognostic signature in breast cancer to predict immune infiltration and therapy response

in Breast Cancer

Hairong Su
Ying Chen
Fengye Lin
Wanhua Li
Xiangyu Gu
Weijie Zeng
Dan Liu
Man Li
Shaowen Zhong
Qianjun Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1325452

2,626 views
1 citation

Review

Published on 13 Dec 2023

TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review

in Breast Cancer

Ying Pan
Qiancheng Zhao
Haitao He
Yubo Qi
Yujie Bai
Jia Zhao
Yiming Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1326023

3,861 views
2 citations

Original Research

Published on 13 Dec 2023

A hematological parameter-based model for distinguishing non-puerperal mastitis from invasive ductal carcinoma

in Breast Cancer

Zhichun Wang
Lin Hua
Xiaofeng Liu
Xueli Chen
Guohui Xue

Frontiers in Oncology

doi 10.3389/fonc.2023.1295656

1,205 views
1 citation

Original Research

Published on 12 Dec 2023

Individualized 3D-printed bolus promotes precise postmastectomy radiotherapy in patients receiving breast reconstruction

in Breast Cancer

Jun Wang
Zhong-zheng Xiang
Chen-feng Tan
Yuan-yuan Zeng
Tian Yang
Xiao-yuan Wei
Si-ting Yu
Ze-lei Dai
Ning-yue Xu
Lei Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1239636

1,592 views

Original Research

Published on 08 Dec 2023

CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation

in Breast Cancer

Ranodeep Chatterjee
Aditya Shukla
Kausiki Chakrabarti
Urmi Chatterji

Frontiers in Oncology

doi 10.3389/fonc.2023.1242432

4,079 views
4 citations

Systematic Review

Published on 07 Dec 2023

Economic evaluation of breast MRI in screening - a systematic review and basic approach to cost-effectiveness analyses

in Breast Cancer

Fabian Tollens
Pascal A.T. Baltzer
Matthias F. Froelich
Clemens G. Kaiser

Frontiers in Oncology

doi 10.3389/fonc.2023.1292268

2,420 views
4 citations

Navigation group

Articles

The importance of cancer-associated fibroblasts in targeted therapies and drug resistance in breast cancer

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

Aromatase inhibitors: the journey from the state of the art to clinical open questions

Cost-effectiveness analysis of elacestrant versus standard endocrine therapy for second-/third-line treatment of patients with HR+/HER2- advanced or metastatic breast cancer: a US payer perspective

Incidence and influencing factors of fertility concerns in breast cancer in young women: a systematic review and meta-analysis

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis

The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study

Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment

Editorial: Case reports in breast cancer : 2022

Establishment of a lysosome-related prognostic signature in breast cancer to predict immune infiltration and therapy response

TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review

A hematological parameter-based model for distinguishing non-puerperal mastitis from invasive ductal carcinoma

Individualized 3D-printed bolus promotes precise postmastectomy radiotherapy in patients receiving breast reconstruction

CLEC12A sensitizes differentially responsive breast cancer cells to the anti-cancer effects of artemisinin by repressing autophagy and inflammation

Economic evaluation of breast MRI in screening - a systematic review and basic approach to cost-effectiveness analyses